YOKNEAM, Israel, March 3, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences in March:
Barclays 27th Annual Global Healthcare Conference
Presenters: Yair Malca, Chief Financial Officer
Format: In-person fireside chat moderated by Matt Miksic, Senior Equity Analyst, and one-on-one meetings
Location: Miami, FL
When: Wednesday, March 12 at 9:00 am EDT
A live webcast of the presentation can be accessed here.
Oppenheimer 34th Annual Healthcare MedTech & Services Conference
Presenters: Moshe Mizrahy, Chief Executive Officer and Yair Malca, Chief Financial Officer
Format: Virtual fireside chat moderated by Suraj Kalia, Senior Equity Analyst, and one-on-one meetings
When: Tuesday, March 18 at 9:20 am EDT
A live webcast of the presentation can be accessed here.
About InMode
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.
Investor Relations Contact:
Miri Segal-Scharia
MS-IR LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$15.31 |
| Daily Change: | 0.09 0.59 |
| Daily Volume: | 597,454 |
| Market Cap: | US$967.750M |
September 02, 2025 July 30, 2025 April 28, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
